Herpes Simplex Clinical Trial
Official title:
Low Dose Versus Weight-based Intravenous Acyclovir for Herpes Simplex Virus Prophylaxis in the Neutropenic Patient
RATIONALE: Acyclovir may be effective in preventing herpes simplex virus infection in
patients with neutropenia.
PURPOSE: This randomized phase III trial is studying the side effects of acyclovir and is
comparing two doses of acyclovir in preventing herpes simplex virus infection in patients
with neutropenia.
OBJECTIVES:
- To determine the difference in nephrotoxicity between low-dose and weight-based
intravenous acyclovir sodium as herpes simplex virus infection prophylaxis in patients
with neutropenia.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive weight-based IV acyclovir sodium every 8 or 12 hours.
- Arm II: Patients receive low-dose IV acyclovir sodium every 8 or 12 hours. Treatment
continues for approximately 2 weeks unless clinical herpes simplex virus infection is
confirmed or the patient is no longer neutropenic.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05468619 -
Neonatal Phase 1 Valacyclovir Study
|
Phase 1 | |
Withdrawn |
NCT02349828 -
Antiviral Prophylaxis in a Burn Population
|
Phase 2/Phase 3 | |
Recruiting |
NCT01176409 -
Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?
|
Phase 3 | |
Completed |
NCT04664127 -
Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
|
||
Completed |
NCT00448227 -
Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection
|
Phase 2 | |
Completed |
NCT00000139 -
Herpetic Eye Disease Study (HEDS) II
|
Phase 3 | |
Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
Completed |
NCT02209324 -
Open-label Study of ASP2151 in Herpes Simplex Patients
|
Phase 3 | |
Completed |
NCT01602562 -
Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients
|
Phase 3 | |
Completed |
NCT00973466 -
Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients
|
N/A | |
Completed |
NCT00698893 -
Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults
|
Phase 1 | |
Active, not recruiting |
NCT05298254 -
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
|
Phase 1/Phase 2 | |
Recruiting |
NCT03178747 -
Tzanck Smear With Methylene Blue Stain for Herpes
|
Phase 3 | |
Completed |
NCT00164424 -
Episodic Acyclovir Therapy for Genital Ulcers
|
Phase 2/Phase 3 | |
Completed |
NCT00161434 -
A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons
|
Phase 4 | |
Terminated |
NCT04762511 -
A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years
|
Phase 1 | |
Completed |
NCT00699764 -
Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease
|
Phase 3 | |
Recruiting |
NCT04065971 -
Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections.
|
Phase 4 | |
Active, not recruiting |
NCT00005663 -
A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients
|
Phase 3 | |
Recruiting |
NCT00006132 -
Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System
|
Phase 3 |